The Helicobacter Pylori Genotyping Among Mongolian Dyspeptic Patients

Objective: The prevalence of H. pylori infection varies significantly and developing countries are found to be the highest in Asia. In the present study, we have aimed to perform a combined analysis of histochemical stains and IHC to confirm the H.pylori infection of patients in 5 different provinces and Ulaanbaatar city, Mongolia. Method: Five hundred and thirty-eight patients were enrolled in this study (142 gastric mucosal atrophy, 333 gastritis and 62 gastroesophageal reflux). Results: 67.1 % of participants had CagA positive and 69.3 % were immunohistochemically positive. All histological results showed that the gastritis group was significantly higher in patients who were positive for H. pylori than in antral-predominant gastritis. By the hematoxylin and eosin staining with May– Giemsa confirmation by IHC, the prevalence of H. pylori infection in the gastric mucosal atrophy group was 62.1 %, while in the gastritis and gastroesophageal reflux group, the rate was 74.3 % and 59.1 %, respectively. Conclusion: CagA sequence profile in each group of patients revealed that 22.6 % of the gastric mucosal atrophy group was ABC type, 43.4 % was ABCC type and 33.9 % was ABTC type. On the other hand, in the gastritis group, the dominant type was ABTC (41.3 %). In the gastroesophageal reflux group, the ABCC type was dominant while 23.1% was the ABC type

Initial Trials With Susceptibility-Based and Empiric Anti-H. pylori Therapies in Mongolia

Background: Mongolia has a high prevalence of Helicobacter pylori infection and gastric cancer. We conducted a prospective, randomized, single-blind study to evaluate the efficacy of common regimens in Mongolia and to obtain specimens for susceptibility testing.Methods: Empiric treatments: 270 patients with confirmed H. pylori infection were randomized to receive 10 days clarithromycin-triple therapy (Clari-TT) (n = 90), modified bismuth quadruple therapy (M-BQT) (n = 90), or sequential therapy (ST) (n = 90). A second group of 46 patients received susceptibility-based Clari-TT. H. pylori was cultured from 131 patients and susceptibility testing was performed. H. pylori eradication was confirmed by stool antigen 4 weeks after the therapy.Results: Intention-to-treat (ITT) analysis cure rates were 71.1% (95% CI = 61.7–80.5%) for Clari-TT, 87.8% (95% CI = 81–94.6%) for M-BQT, 67.8% (95% CI = 58.1–77.5%) for ST vs. 89.1% (95% CI = 86–98.2%) for susceptibility-based Clari-TT. Per-protocol (PP) analysis results for these therapies were 72.7% (63.4–82%), 89.8% (83.5–96.1%), 68.5% (58.8–78.2%), and 97.6% (89.5–99.8%), respectively. Among 131 cultured H. pylori, resistance rates to amoxicillin, clarithromycin, and metronidazole were 8.4, 37.4, and 74%, respectively.Conclusion: In Mongolia, the prevalence of H. pylori resistance is high requiring bismuth quadruple therapy or susceptibility-based therapy to obtain acceptable cure rates